Wilovast

Wilovast

rosuvastatin

Manufacturer:

Hizon Laboratories, Inc

Distributor:

Willore Pharma
Concise Prescribing Info
Contents
Rosuvastatin Ca
Indications/Uses
Hyperlipidaemias, including primary hypercholesterolaemia (type IIa), mixed dyslipidaemia (type IIb) & hypertriglyceridaemia (type IV). HoFH.
Dosage/Direction for Use
Initially 5-10 mg in the evening. Ischaemic heart disease Initially 20 mg, may be adjusted at interval of not <4 wk up to max 80 mg once daily in 3 divided doses of 20 mg, 20 mg & 40 mg evening dose. Patient taking cyclosporine, fibric acid derivatives or nicotinic acid & at risk of myopathy Max: 10 mg once daily.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Active liver disease or w/ unexplained persistent elevations of serum transaminases. Pregnancy & lactation.
Special Precautions
History of liver disease &/or consume substantial quantities of alcohol. Patients w/ predisposing factors for myopathy eg, renal impairment, advanced age & inadequately treated hypothyroidism. Uncomplicated myalgia & myopathy. Discontinue use if markedly elevated CK levels occur or myopathy is diagnosed or suspected. Therapy should be temporarily w/held in any patient w/ an acute, serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis (eg, sepsis, hypotension, dehydration, major surgery, trauma, severe metabolic endocrine & electrolyte disorder or uncontrolled seizures). Avoid combination therapy w/ gemfibrozil.
Adverse Reactions
Thrombocytopenia; hepatitis, jaundice, fatal & non-fatal hepatic failure; arthralgia; peripheral neuropathy; depression, sleep disorders (including insomnia & nightmares); gynecomastia; ILD; DRESS, lichenoid drug eruption.
Drug Interactions
Increased AUC w/ cyclosporin, teriflunomide, capmatinib, fostamatinib, febuxostat & darolutamide. Increased risk of myopathy & rhabdomyolysis w/ gemfibrozil, tafamidis & regorafenib; other lipid lowering therapies, cyclosporine; fenofibrates, niacin (≥ 1 g/day) & colchicine; simeprevir, dasabuvir/ombitasvir/paritaprevir/ritonavir, elbasvir/grazoprevir, sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, atazanavir/ritonavir, lopinavir/ritonavir & voxilaprevir. Decreased plasma conc w/ antacid susp containing Al & Mg hydroxide. Rise in INR w/ warfarin.
MIMS Class
Dyslipidaemic Agents
ATC Classification
C10AA07 - rosuvastatin ; Belongs to the class of HMG CoA reductase inhibitors. Used in the treatment of hyperlipidemia.
Presentation/Packing
Form
Wilovast FC tab 10 mg
Packing/Price
100's (P2,450/box, P24.5/film-coated tab)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in